YAP/TEAD involvement in resistance to paclitaxel chemotherapy in lung cancer.
Chemo-resistance
Lung cancer
Microfluidics
Paclitaxel
TEAD
YAP (yes-associated protein)
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
15
10
2023
accepted:
23
01
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
The Yes-associated protein (YAP) oncoprotein has been linked to both metastases and resistance to targeted therapy of lung cancer cells. We aimed to investigate the effect of YAP pharmacological inhibition, using YAP/TEA domain (TEAD) transcription factor interaction inhibitors in chemo-resistant lung cancer cells. YAP subcellular localization, as a readout for YAP activation, cell migration, and TEAD transcription factor functional transcriptional activity were investigated in cancer cell lines with up-regulated YAP, with and without YAP/TEAD interaction inhibitors. Parental (A549) and paclitaxel-resistant (A549R) cell transcriptomes were analyzed. The half-maximal inhibitory concentration (IC
Identifiants
pubmed: 38427166
doi: 10.1007/s11010-024-04949-7
pii: 10.1007/s11010-024-04949-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR 20217 Hippocure
Organisme : Agence Nationale de la Recherche
ID : ANR 20217 Hippocure
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Global Cancer Observatory [Internet]. [cité 5 oct 2022]. Disponible sur: https://gco.iarc.fr/
Nguyen CDK, Yi C (2019) YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer 5(5):283–296
doi: 10.1016/j.trecan.2019.02.010
pubmed: 31174841
pmcid: 6557283
Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D et al (2014) Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res 74(19):5421–5434
doi: 10.1158/0008-5472.CAN-14-0067
pubmed: 25274031
pmcid: 4185415
Han ZX, Wang HM, Jiang G, Du XP, Gao XY, Pei DS (2013) Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2. Cancer Biother Radiopharm 28(5):398–405
pubmed: 23496232
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of Taxol resistance related to microtubules. Oncogene 22(47):7280–7295
doi: 10.1038/sj.onc.1206934
pubmed: 14576838
pmcid: 4039039
Monzó M, Rosell R, Sánchez JJ, Lee JS, O’Brate A, González-Larriba JL et al (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17(6):1786–1793
doi: 10.1200/JCO.1999.17.6.1786
pubmed: 10561216
Zhao B, Li L, Lei Q, Guan KL (2010) The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24(9):862–874
doi: 10.1101/gad.1909210
pubmed: 20439427
pmcid: 2861185
Avruch J, Zhou D, Fitamant J, Bardeesy N, Mou F, Barrufet LR (2012) Protein kinases of the Hippo pathway: regulation and substrates. Semin Cell Dev Biol 23(7):770–784
doi: 10.1016/j.semcdb.2012.07.002
pubmed: 22898666
pmcid: 3489012
Battilana G, Zanconato F, Piccolo S (2021) Mechanisms of YAP/TAZ transcriptional control. Cell Stress 5(11):167–172
doi: 10.15698/cst2021.11.258
pubmed: 34782888
pmcid: 8561301
Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X (2010) Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 101(5):1279–1285
doi: 10.1111/j.1349-7006.2010.01511.x
pubmed: 20219076
de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M et al (2012) An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res 18(10):2976–2986
doi: 10.1158/1078-0432.CCR-11-2797
pubmed: 22434665
Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell 29(6):783–803
doi: 10.1016/j.ccell.2016.05.005
pubmed: 27300434
pmcid: 6186419
Tang Z, Ma Q, Wang L, Liu C, Gao H, Yang Z et al (2019) A brief review: some compounds targeting YAP against malignancies. Future Oncol 15(13):1535–1543
doi: 10.2217/fon-2019-0035
pubmed: 31066301
Sebio A, Lenz HJ (2015) Molecular pathways: hippo signaling, a critical tumor suppressor. Clin Cancer Res 21(22):5002–5007
doi: 10.1158/1078-0432.CCR-15-0411
pubmed: 26384319
pmcid: 4644679
Fromond C, Espanel X, Soudé A, Chene L, Masson, P Boubia B, Montalbetti C, Broqua P. A rational approach for the discovery of inhibitors of the YAP-TEAD interaction” Proceedings of the 106
Soudé A, Barth M, Luccarini JM, Delaporte S, Chirade F, Valaire C, et al. Discovery of YAP-TEAD Protein-Protein Interaction inhibitors (PPI) for treating Malignant Pleural Mesothelioma (MPM)” ACR Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond, May 8–11 San Diego 2020. Mol Cancer Res. 2020, 18 (8 _Suppl.) Abst.nr B14
Dubois F, Keller M, Calvayrac O, Soncin F, Hoa L, Hergovich A et al (2016) RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway. Cancer Res 76(6):1627–1640
doi: 10.1158/0008-5472.CAN-15-1008
pubmed: 26759237
Keller M, Dubois F, Teulier S, Martin APJ, Levallet J, Maille E et al (2019) NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. J Exp Clin Cancer Res 38(1):158
doi: 10.1186/s13046-019-1145-8
pubmed: 30979377
pmcid: 6461807
Sontheimer-Phelps A, Hassell BA, Ingber DE (2019) Modelling cancer in microfluidic human organs-on-chips. Nat Rev Cancer 19(2):65–81
doi: 10.1038/s41568-018-0104-6
pubmed: 30647431
Nguyen M, De Ninno A, Mencattini A, Mermet-Meillon F, Fornabaio G, Evans SS et al (2018) Dissecting effects of anti-cancer drugs and cancer-associated fibroblasts by on-chip reconstitution of immunocompetent tumor microenvironments. Cell Rep 25(13):3884-3893.e3
doi: 10.1016/j.celrep.2018.12.015
pubmed: 30590056
Portillo-Lara R, Annabi N (2016) Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment. Lab Chip 16(21):4063–4081
doi: 10.1039/C6LC00718J
pubmed: 27605305
Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E et al (2019) MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. Br J Cancer 120(4):387–397
doi: 10.1038/s41416-019-0379-8
pubmed: 30739911
pmcid: 6461894
Deforet M, Parrini MC, Petitjean L, Biondini M, Buguin A, Camonis J et al (2012) Automated velocity mapping of migrating cell populations (AVeMap). Nat Methods 9(11):1081–1083
doi: 10.1038/nmeth.2209
pubmed: 23064519
Veith I, Mencattini A, Picant V, Serra M, Leclerc M, Comes MC et al (2021) Apoptosis mapping in space and time of 3D tumor ecosystems reveals transmissibility of cytotoxic cancer death. PLoS Comput Biol 17(3):e1008870
doi: 10.1371/journal.pcbi.1008870
pubmed: 33784299
pmcid: 8034728
Corgnac S, Damei I, Gros G, Caidi A, Terry S, Chouaib S et al (2022) Cancer stem-like cells evade CD8+CD103+ tumor-resident memory T (TRM) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model. J Immunother Cancer 10(4):e004527
doi: 10.1136/jitc-2022-004527
pubmed: 35418483
pmcid: 9014106
Biondini M, Duclos G, Meyer-Schaller N, Silberzan P, Camonis J, Parrini MC (2015) RalB regulates contractility-driven cancer dissemination upon TGFβ stimulation via the RhoGEF GEF-H1. Sci Rep 5:11759
doi: 10.1038/srep11759
pubmed: 26152517
pmcid: 4495419
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E et al (2015) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47(3):250–256
doi: 10.1038/ng.3218
pubmed: 25665005
pmcid: 4930244
Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M et al (2011) Role of YAP/TAZ in mechanotransduction. Nature 474(7350):179–183
doi: 10.1038/nature10137
pubmed: 21654799
Stein C, Bardet AF, Roma G, Bergling S, Clay I, Ruchti A et al (2015) YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers. PLoS Genet 11(8):e1005465
doi: 10.1371/journal.pgen.1005465
pubmed: 26295846
pmcid: 4546604
Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B et al (2015) Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 17(9):1218–1227
doi: 10.1038/ncb3216
pubmed: 26258633
pmcid: 6186417
Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, Lian JB, Stein GZ (2004) Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 23(4):790–799
doi: 10.1038/sj.emboj.7600073
pubmed: 14765127
pmcid: 380991
Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P et al (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci 115(26):E630–E638
doi: 10.1073/pnas.1717782115
Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z et al (2016) YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget 7(32):51922–51933
doi: 10.18632/oncotarget.10458
pubmed: 27409162
pmcid: 5239524
Esposito D, Pant I, Shen Y, Qiao RF, Yang X, Bai Y et al (2022) ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. Nat Commun 13(1):703
doi: 10.1038/s41467-022-28319-3
pubmed: 35121738
pmcid: 8817028
Stewart DJ (2010) Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol Sept 75(3):173–234
doi: 10.1016/j.critrevonc.2009.11.006
Stewart DJ (2013) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djt356
doi: 10.1093/jnci/djt356
pubmed: 24309006
Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C et al (2021) YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv 7(40):eabd1850
doi: 10.1126/sciadv.abg1850
Decaudin D (2011) Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer. Anticancer Drugs 22(9):827–841
doi: 10.1097/CAD.0b013e3283475f70
pubmed: 21623183
Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE (2010) Reconstituting organ-level lung functions on a chip. Science 328(5986):1662–1668
doi: 10.1126/science.1188302
pubmed: 20576885
pmcid: 8335790
Benam KH, Villenave R, Lucchesi C, Varone A, Hubeau C, Lee HH et al (2016) Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 13(2):151–157
doi: 10.1038/nmeth.3697
pubmed: 26689262
Jain A, Barrile R, van der Meer AD, Mammoto A, Mammoto T, De Ceunynck K et al (2018) Primary human lung alveolus-on-a-chip model of intravascular thrombosis for assessment of therapeutics. Clin Pharmacol Ther 103(2):332–340
doi: 10.1002/cpt.742
pubmed: 28516446
Mencattini A, Lansche C, Veith I, Erbs P, Balloul JM, Quemeneur E et al (2022) Direct imaging and automatic analysis in tumor-on-chip reveal cooperative antitumoral activity of immune cells and oncolytic vaccinia virus. Biosens Bioelectron 215:114571
doi: 10.1016/j.bios.2022.114571
pubmed: 35932554